Bengaluru: BMCRI likely to suspend trials of Dr Giridhar Kaje’s ayurvedic tablets
Team Udayavani, Aug 2, 2020, 3:43 PM IST
Bengaluru: The ethics committee of the Bangalore Medical College and Research Institute (BMCRI) has issued a notice to Bengaluru-based ayurvedic medical practitioner named Dr Giridhar Kaje for claiming the success of the trials of tablets — Bhoumya and Saathmya – without presenting it to the committee.
The BMCRI has also decided to suspend the clinical trials for ayurvedic tablets — Bhoumya and Saathmya — which were introduced to cure COVID-19 by Dr Giridhar Kaje.
In a letter to Dr Kaje, BMCRI said, “Though the trial is still in its preliminary stage and no results have been placed before the ethics committee of BMCRI, you have gone to the public claiming success of the Trial. This is unacceptable and amounts to overstepping of one’s responsibility.”
“You must immediately clarify in the media the factual position as otherwise we will be force to suspend the trial due to the unauthorised act of yours in misleading the public,” the letter added.
However, Kaje has denied all the allegations.
UPSC announces 2019 civil services exam results, Pradeep Singh secures top position
US doing ”very well” against COVID-19, India has a ”tremendous problem”: Trump
Landslide on WEH after heavy rain, traffic movement affected
Related Articles More
Covid-19: Jubilant Life Sciences launches generic version of remdesivir
India’s COVID-19 tally climbs to 18,55,745; Recovery rate rises to 66.31 pc
WHO advance team ends visit to China to probe COVID origin
Siddaramaiah tests positive for COVID-19
K’taka COVID-19 update: 4752 new cases; 4776 discharges; 98 deaths
Disposed PPEs could be turned into biofuel, say Indian scientists
Brand Nexa: A success story from Maruti stable
Ayana Renewable acquires two solar power assets of First Solar in Karnataka
Hindutva now basic coat on canvas of Indian politics: Govindacharya
Sushant Singh Rajput case: Maha slams CBI probe recommendation